To validate Trop2 as a prognostic tissue biomarker for clinically significant prostate cancer, we assessed tissue levels of Trop2 in the Canary Prostate Cancer Tissue Microarray (CPCTA) that was constructed from prostate cancer tissues from 1328 patients from 7 institutions with a minimum of 5 years follow-up (Fig. 1A)19. The gene discussed is TACSTD2; the disease is prostate carcinoma.